|
Aminoglycosides [71]
|
|
PTC readthrough
|
Toxic at clinical active concentrations
|
|
Caffeine [72]
|
|
SMG1 inhibition
|
Toxicity, highly aspecific by targeting several kinases
|
|
NMDI-1 [73, 74]
|
|
Stabilization of the phosphorylated form of UPF1
|
No side effects in mice
|
|
5-azacytidine [75]
|
|
Non identified, but c-MYC-mediated
|
Already approved for the treatment of diverse malignancies
|
|
Amlexanox [76]
|
|
Inhibits NMD at a late stage
|
Clinically approved for aphthous ulcers
|
|
NMDI14 [77]
|
|
Disrupts the SMG7–UPF1 complex
|
Negligible toxicity in cell-based assays
|
